Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity

• Status: Terminated
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to 75 mg clopidogrel after elective percutaneous coronary intervention.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pecs
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Clopidogrel-naïve stable angina pectoris (CCS I-III)

• Coronary angiography that reveals significant DE NOVO coronary stenosis (diameter stenosis greater than 50% in two independent projections) feasible for ad hoc stent implantation

Exclusion Criteria:

• Acute coronary syndrome (STEMI, NSTEMI or unstable angina)

• Administration of clopidogrel/ticlopidine/coumarin in the past 6 weeks

• Contraindication to antiplatelet therapy

• Significant LM stenosis

• PCI due to instent restenosis

• Lesion located in bypass grafts

• Stroke in past one year

• Reduced life expectancy